Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | POLQ | O75417 | 6/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991942 | 0.89 | MAPK1 (0.40) | MEN1ALDH1A1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL18241901 | 0.83 | DAO (0.51) | DAOPOLQIDO1CES2 | |
| SCHEMBL6101647 | 0.78 | TYR (0.39) | MEN1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL23661917 | 0.76 | CES2 (0.43) | DAOPOLQCES2MEN1ALDH1A1 | |
| SCHEMBL677114 | 0.75 | MAPK1 (0.42) | MEN1ALDH1A1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL21534433 | 0.75 | KIF11 (0.40) | POLQCES2MEN1ALDH1A1MAPK1 | |
| SCHEMBL18768786 | 0.75 | PDE2A (0.44) | POLQIDO1CES2MEN1ALDH1A1 | |
| SCHEMBL18242683 | 0.73 | DAO (0.49) | DAOPOLQIDO1CES2 | |
| SCHEMBL20125681 | 0.73 | MAPT (0.38) | POLQCES2MEN1ALDH1A1MAPK1 | |
| SCHEMBL13349970 | 0.73 | DAO (0.51) | DAOPOLQIDO1CES2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984639-B2 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050059693-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | GPI NIL HOLDINGS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-6417209-B2 | NON-IMMUNOSUPPRESSIVE, PIPERIDINO OR PYRROLIDINO AMIDE DERIVATIVE HAS AN AFFINITY FOR AN FKBP-TYPE IMMUNOPHILIN, USEFUL FOR TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS | GPI NIL HOLDINGS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6274602-B1 | ADMINISTERING COMPOSTITIONS SUCH AS 3,3-DIMETHYL-1-((2S)-2-(5-(3-PYRIDYL) PENTANOYL)-1-PYRROLIDINE)-1, 2-PENTANEDIONE TO TREAT ALOPECIA OR PROMOTING HAIR GROWTH IN ANIMALS | GPI NIL HOLDINGS, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059693-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | ACOT7, HSD17B7, ZDHHC7 | DAO 1381/4885POLQ 3405/4885IDO1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.